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A B S T R A C T
Community pharmacies have great potential to deliver services aimed at promoting health and preventing
disease, and are well placed in deprived communities. This review of reviews aimed to assess the effectiveness of
community pharmacy-delivered public health services and assess how they impact on inequalities in health
using PROGRESS-Plus characteristics. Twenty databases were searched from their start date until January 2018.
The quality of the included articles was determined using the Assessment of Multiple Systematic Reviews tool
(AMSTAR 2). Fifteen systematic reviews were identified reporting 157 unique primary studies. There were a
number of community pharmacy initiatives with positive intervention effects on health outcomes. These services
were predominantly focused on primary disease prevention, and included smoking cessation, weight manage-
ment programmes, syringe exchange programmes, and inoculation services. This review supports the develop-
ment of some community pharmacy public health services. At present, little is known how community phar-
macy-delivered public health interventions impact on health inequalities. It would be prudent for future studies
to address this by explicitly reporting outcomes according to the PROGRESS-Plus framework.
Systematic review registration: PROSPERO registration number: CRD42017056264.
1. Background
Community pharmacies have emerged as strategically important
settings that have great potential to deliver services aimed at promoting
health, and preventing disease. In many countries, the community
pharmacist is the most accessible healthcare provider to the general
public: they are available without an appointment, are open evenings
and weekends, and are often located in the most deprived communities
(the ‘positive pharmacy care law’ (Todd et al., 2014)). Community
pharmacies are thereby ideally placed to offer public health and
healthcare services to the most deprived communities.
In recent decades, the role of the community pharmacist has un-
dergone rapid expansion, with many services moving away from the
traditional supply function to more patient-focused services (Anderson,
2007). Indeed, many community pharmacists now offer a range health
promotion activities aimed at either primary or secondary disease
prevention. Accompanying this shift, the literature surrounding the
extended role of the community pharmacist has also expanded – with
many groups producing systematic reviews examining the effectiveness
of such interventions (Brown et al., 2016). Previous systematic reviews
have predominantly focused on single interventions, and have not ex-
plored intervention effectiveness at the primary or secondary preven-
tion level, making it challenging to determine where community
pharmacy-delivered interventions fit within the wider disease preven-
tion agenda. At present, there is no comprehensive review that seeks to
examine the effectiveness of all community pharmacy-delivered public
health services, or explore how the effects of these services are mod-
erated by socio-demographic factors. This later point has been
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highlighted by the UK National Institute of Health and Care Excellence
(NICE) as a research priority to ensure the potential of community
pharmacy-delivered public health interventions in reducing health in-
equalities can be maximised (NICE, 2018). A wide, and comprehensive,
review of community pharmacy-delivered public health interventions is
needed to inform policy, but also to identify gaps and inform future
research endeavours. In this paper, we undertake a ‘review of reviews’
of community pharmacy-delivered public health services and seek to
determine how they impact on health and inequalities in health. A re-
view of reviews is an established and effective way of bringing together
and summarising a broad evidence-base (Becker and Oxman, 2008) and
has been used for a number of public health topics (Bambra et al., 2010;
Cairns et al., 2015; Hill et al., 2014; Main et al., 2008).
2. Methods
The full methodology for this work has been previously described in
the published protocol (Hillier-Brown et al., 2017). The review is also
registered with PROSPERO (CRD42017056264), while a completed
PRISMA checklist is also included in Appendix S1.
2.1. Research questions
1. What is the effectiveness of community pharmacy-delivered public
health interventions?
2. How are the intervention effects moderated according to PROGR-
ESS-Plus factors?
2.2. Inclusion criteria
Following standard evidence synthesis approaches (Kavanagh et al.,
2008), the inclusion criteria for the review were determined a priori in
terms of PICOS (Population, Intervention, Comparison, Outcome and
Study design (Higgins and Green, 2011)).
• Population: Children and adults (all ages) in any country.• Intervention: Public health interventions delivered in community
pharmacy settings. For the purposes of the review, a public health
intervention was described as any intervention designed to prevent
disease, promote health and prolong life; specifically, we focused on
interventions aimed at the primary prevention (preventing the onset
of disease) or secondary prevention level (detecting disease in the
early stages). A community pharmacy was defined as a pharmacy set
in the community, which is accessible to all and not based in a
hospital, clinic or GP surgery.• Comparison: Systematic reviews that included studies with and
without controls, including randomized and nonrandomized con-
trolled trials, randomized and nonrandomized cluster trials, pro-
spective and retrospective cohort studies (with and/or without
control groups), prospective repeat cross-sectional studies (with
and/or without control groups) and interrupted time series analysis
(with and/or without control groups).• Outcomes: To answer our primary research question, we included
health outcome data, and to answer our secondary research ques-
tion, we included health inequality outcomes. Primary outcomes
included health outcomes, physiology and biochemical outcomes,
and behavioural outcomes. Secondary outcomes related to how the
effects of the interventions were moderated in terms of PROGR-
ESS-Plus factors: place of residence, race/ethnicity, occupation,
gender, religion, education, socio-economic status (defined as: in-
dividual income, wealth, education, employment or occupational
status, benefit receipt; as well as area-level economic indicators),
social capital, age, disability and sexual orientation. When available,
cost effectiveness data was also collected.• Study design: Only systematic reviews were included in the ana-
lysis. Following the methods of previous review of reviews (Bambra
et al., 2010; Cairns et al., 2015), publications needed to meet two of
the three mandatory criteria of Database of Abstracts of Reviews of
Effects (DARE): (i) that there is a defined review question (with
definition of at least two of, the participants, interventions, out-
comes or study designs) and (ii) that the search strategy included at
least one named database, in conjunction with either reference
checking, hand-searching, citation searching or contact with authors
in the field.
2.3. Exclusion criteria
We excluded interventions that focused on promoting medicine
adherence, or medicine optimisation; we also excluded any interven-
tion aimed at tertiary disease prevention (reducing symptoms of an
established disease).
2.4. Search strategy
Twenty databases were searched until January 2018 (host sites given
in parentheses): Medline (Ovid), Embase (Ovid), Cumulative Index to
Nursing and Allied Health Literature (CINAHL; EBSCOhost), PsycINFO
(EBSCOhost), Social Science Citation Index (Web of Science), Applied
Social Sciences Index and Abstracts (ASSIA; ProQuest), International
Bibliography of the Social Sciences (IBSS; ProQuest), Sociological
Abstracts (ProQuest), Social Services Abstracts (ProQuest), Prospero
(Centre for Reviews and Dissemination, University of York), Campbell
Collaboration Library of Systematic Reviews (The Campbell Library),
Cochrane Library (includes Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials, Cochrane Methodology
Register, Database of Abstracts of Reviews of Effects, Health Technology
Assessment Database, NHS Economic Evaluation Database; Wiley),
Database of Promoting Health Effectiveness Reviews (DoPHER; EPPI-
Centre), Social Care Online (SCIE) and Health Systems Evidence.
Searches were tailored to the specific host site (full search strategies
are shown in Appendix S2). In addition, citation follow up from the
bibliographies and reference lists of all included articles was conducted.
Searches were limited to peer-reviewed publications only. No language
or publication date restrictions were applied. Authors were contacted to
obtain relevant information that was missing. If systematic reviews did
not have sufficient data, they were excluded from further analysis.
2.5. Study selection, data extraction and quality appraisal
Study selection was conducted by three reviewers independently
with cross-checking (FHB, NW, KT). Agreement between the reviewers
was 99% with a kappa score of good (κ=0.68) (Higgins and Deeks,
2011). The methods and main findings were extracted using a bespoke
data extraction form (detailed in Appendix S3). The quality of each
systematic review was determined using the updated version of the
Assessment of Multiple Systematic Reviews: AMSTAR 2 (Shea et al.,
2017). Data extraction and quality appraisal was conducted by three
reviewers (KT, FHB and NW) and checked in full by KT or AT. Any
discrepancies were resolved through discussion and consensus.
2.6. Data synthesis
The systematic reviews were narratively synthesised by intervention
type. Effect sizes from meta-analyses were considered when available.
3. Results
A total of 16,827 citations were retrieved from the twenty databases
searched. Deduplication resulted in 12,066 unique citations. Reasons
for exclusion at the full text stage are detailed in Appendix S4. In total,
15 systematic reviews (Tables 1–8) were included in our review, re-
porting 157 unique primary studies (Fig. 1).
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Assessment with AMSTAR2 revealed: two reviews had one weakness
(Elias et al., 2011; Sinclair et al., 2004), three reviews had two weak-
nesses (Brown et al., 2016; Gordon et al., 2011; Sawangjit et al., 2016),
three reviews had three weaknesses (Blenkinsopp et al., 2003; Gudka
et al., 2013; Lindsey et al., 2015), three reviews had four critical do-
main weaknesses (Ayorinde et al., 2013; Saba et al., 2014; Watson and
Blenkinsopp, 2009), while four reviews (Burson et al., 2016; Kapadia,
2013; Nacopoulos et al., 2010; Nguyen, 2017) had weaknesses in five
out of the seven possible critical domains (no reviews had zero critical
domain weaknesses) (Appendix S5).
The reviews covered six different public health intervention areas.
Interventions aimed at primary prevention included: smoking cessation
(n=2) (Saba et al., 2014; Sinclair et al., 2004); weight management
(n=1) (Gordon et al., 2011); alcohol misuse (n= 1) (Watson and
Blenkinsopp, 2009); syringe/needle exchange programmes (n= 2)
(Nacopoulos et al., 2010; Sawangjit et al., 2016); inoculation services
(n=1) (Burson et al., 2016). Two of the included reviews were multi-
component, exploring a range of public health interventions (n= 2)
(Blenkinsopp et al., 2003; Brown et al., 2016). Interventions aimed at
secondary prevention included those directed at screening services,
which ranged from cancer to osteoporosis screening (n= 4) (Ayorinde
et al., 2013; Elias et al., 2011; Lindsey et al., 2015; Nguyen, 2017), and
chlamydia testing (Gudka et al., 2013; Kapadia, 2013). Seven of the
reviews looked at health inequalities (Brown et al., 2016; Burson et al.,
2016; Elias et al., 2011; Gudka et al., 2013; Kapadia, 2013; Lindsey
et al., 2015; Nacopoulos et al., 2010) and 16% of primary studies were
reported in more than one systematic review (see Appendix S6).
3.1. Primary prevention
3.1.1. Smoking cessation
Two reviews (reporting five unique studies) focused on smoking
cessation interventions and included a combination of advice, educa-
tion or nicotine replacement therapy (NRT). Both reviews showed im-
provements in health as measured by cessation rates (Table 1). The first
review by Sinclair et al. (2004) found two relevant primary studies,
both of which were RCTs conducted in the UK. These studies compared
a support programme of counselling with a control group who received
normal service from community pharmacy personnel. Both studies re-
ported an improvement in self-reported cessation rates: one study re-
ported at 12months (14.3% versus 2.7%, p < 0.001), while the other
study showed a positive outcome at 9months (12.0% versus 7.4%,
p=0.09).
The second review, a meta-analysis by Saba et al. (2014), also as-
sessed the effectiveness of smoking cessation interventions in commu-
nity pharmacies. It included five relevant studies (three RCTs and two
controlled before and after studies) from the USA, UK and Sweden. The
interventions in these studies provided advice and counselling to pa-
tients, either on a one-to-one basis or in group sessions. The results
suggested that smoking cessation interventions delivered by community
Fig. 1. PRISMA flow diagram.
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pharmacists resulted in better abstinence rates when compared with
controls (RR 2.17, 95% CI 1.43, 3.31). There was also evidence that the
use of NRT alongside counselling yielded higher abstinence rates (RR
3.46, 95% CI 1.66, 7.23).
3.1.2. Weight management
A systematic review by Gordon et al. (2011) explored the effec-
tiveness of community pharmacy-delivered weight management inter-
ventions (Table 2) and concluded there was insufficient evidence for
their effectiveness. Of the 10 primary studies included, one was also
reported in the multi-component review, undertaken by Brown et al.
(2016). Studies from this review were conducted in the USA, UK,
Switzerland, Spain and Denmark. All of the interventions included in
this review had multiple components and focused on dietary advice,
improving physical activity, meal replacement, or using pharma-
cotherapy to promote weight loss. Overall, modest, but significant,
weight loss among participants was reported in all of the studies, al-
though the review acknowledged the included studies had reporting
and methodological weaknesses. In view of this, the authors of the re-
view concluded that there was insufficient evidence for the effective-
ness and cost effectiveness of community pharmacy-based weight
management initiatives to support investment in their provision.
3.1.3. Alcohol misuse
A single review by Watson and Blenkinsopp (2009) examined the
feasibility of providing community pharmacy-based services for alcohol
misuse (Table 3). The review included three relevant primary studies
conducted in the UK that used approaches to identify hazardous and
harmful drinking. The studies found non-significant reductions in al-
cohol consumption following brief interventions.
3.1.4. Syringe/needle exchange programmes
Two reviews examined the impact of syringe/needle exchange
programmes (SEPs) based in community pharmacies for intravenous
drug users (Table 4), and showed a clear effect in improving health
outcomes. In total, twenty-eight unique primary studies were identified
by the two reviews (one study was duplicated in both reviews).
The first review, by Nacopoulos et al. (2010), which synthesised
evidence from 16 primary studies conducted in the USA, concluded that
such interventions can have a positive effect on health outcomes by
reducing high-risk injecting behaviours. The work also demonstrated
that people using SEPs had lower rates of injection frequency, un-
employment, jail time, homelessness, smoking, and alcohol use com-
pared with intravenous drug users who do not participate in SEPs.
The second review, by Sawangjit et al. (2016), included evidence
from 13 studies – the majority of which were undertaken in the USA,
although studies from the UK, Australia, Estonia, and Canada were also
included. The review found that community pharmacy-based SEPs were
effective in reducing high-risk behaviours among intravenous drug
users (e.g. syringe-sharing behaviour). When only higher quality studies
were considered, syringe-sharing behaviour was significantly better in
community pharmacy-based SEPs compared to no SEPs (OR=0.52;
95% CI= 0.32, 0.84; I2= 41.4%).
3.1.5. Inoculation services
One systematic review examined the health effects of inoculation
services offered by community pharmacies (Table 5). The review, by
Burson et al. (2016), concluded that pharmacy-based immunisation
interventions are capable of improving access to immunisation services,
which has the potential to increase vaccination rates. In total, 17 pri-
mary studies included in this review were relevant to our review; 16 of
the studies were conducted in the USA, and one was conducted in
Puerto Rico. Most notably, community pharmacy-based services were
effective in increasing influenza vaccination rates among people who
had missed vaccination the previous year, or would have not otherwise
received a vaccine. Evidence from the review also showed that nearlyTa
bl
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one third of the vaccines were administered outside the traditional
working day (such as evenings and weekends), highlighting the unique
accessibility of the community pharmacy network.
3.1.6. Reviews examining multiple interventions
Two systematic reviews examined a variety of public health inter-
ventions undertaken by community pharmacies (Table 6). The review
by Blenkinsopp et al. (2003) examined the effectiveness of community
pharmacy interventions to reduce risk behaviours and risk factors as-
sociated with coronary heart disease (smoking cessation, lipid man-
agement and blood pressure management). The review included 11
relevant studies, which were conducted in the USA, UK, Switzerland,
Sweden, and Canada. The authors concluded that, through a combi-
nation of testing and counselling approaches, improvements in health
could result from smoking cessation and lipid lowering interventions
conducted in community pharmacies. Another review, by Brown et al.
(2016), explored the effectiveness of community pharmacy-delivered
interventions for alcohol reduction, smoking cessation and weight
management. Nineteen relevant studies were included from the UK,
USA, Australia, Canada, Netherlands, Denmark, Japan and Thailand.
Pharmacy-based smoking cessation interventions (n= 12) including
behavioural support and/or nicotine replacement therapy were shown
to be both effective and cost-effective, particularly when compared with
usual care. The pooled odds ratio for the intervention effects for
smoking cessation was 2.56 (95% CI 1.45, 4.53). Evidence from two
alcohol-reduction interventions was, however, limited, while commu-
nity pharmacy-based weight management interventions (n=5) were
shown to be as effective as similar interventions in other primary care
settings (at least in the short term), and had similar provider costs.
3.2. Secondary prevention
3.2.1. Screening
Four systematic reviews examined the impact of screening inter-
ventions from a community pharmacy setting: one for major diseases
(Ayorinde et al., 2013), one on cancer screening (Lindsey et al., 2015),
and two on osteoporosis screening (Elias et al., 2011; Nguyen, 2017)
(Table 7). Overall, the results demonstrated that it was feasible to de-
liver screening interventions from community pharmacies, although it
was not clear how these interventions impacted on health outcomes in
terms of early diagnosis of disease.
The review by Ayorinde et al. (2013) included 50 relevant studies
drawn from the USA, Australia, Germany, Korea and Spain. The review
focused on a variety of major diseases, including cardiovascular, mus-
culoskeletal, diabetes, depression, sleep disorders, respiratory diseases,
and some cancers. Some screening approaches targeted ‘at risk’ in-
dividuals, while others screened an apparently healthy population;
some interventions used both approaches, and targeted normal popu-
lations and ‘at risk’ individuals. The proportion of individuals that
screened positively for either disease or disease risk factors ranged
between 4% and 89%. Although patient satisfaction was high, the re-
view authors noted it was common for patients who screened positive
to ignore pharmacist referral to seek further medical attention in order
to confirm the presence of disease through diagnostic testing.
The second review, by Lindsey et al. (2015), investigated education
and screening interventions to promote the early detection of cancer
(colorectal, prostate, breast and cervical cancer). The review included
12 primary studies conducted in the USA, Australia, Italy, Germany,
Korea, and Spain. The work concluded that, although it was feasible to
recruit patients to screening interventions in a community pharmacy
setting, the interventions were poorly described (particularly in terms
of delivery, education and fidelity) and that more evidence was needed
to ascertain how such interventions impact on overall cancer survival.
Two reviews focused on osteoporosis screening by community
pharmacies, both drawing from studies conducted in the USA, Canada
and Australia. The review by Elias et al. (2011) included three primaryTa
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studies. Interventions were shown to improve the uptake of bone mi-
neral density testing (diagnostic test of osteoporosis); people who were
identified as being at a high risk of developing osteoporosis were also
shown to increase their daily calcium intake. A similar review by
Nguyen (2017) included nine relevant primary studies, although all but
one of the studies was reported in the reviews by either Elias et al.
(2011) or Ayorinde et al. (2013). This review found community phar-
macy-based osteoporosis screening services to provide a cost-effective
approach to preventing osteoporotic fractures for population health.
Improvements relating to osteoporosis knowledge, risk identification,
and increasing calcium intake were identified as integral components of
a successful intervention.
3.2.2. Chlamydia testing
Two reviews reported on interventions to promote chlamydia
testing (Chlamydia trachomatis) through community pharmacies
(Table 8), and found a high level of patient acceptance and use. The
review by Kapadia (2013) focused on assessing chlamydia prevalence,
and included 11 relevant primary studies conducted in the UK, USA,
The Netherlands or Australia; the majority of the testing programmes
were aimed at people seeking emergency hormonal contraception from
community pharmacies. The meta-analysis showed a chlamydia posi-
tivity of 8.1% (95% CI 7.3, 8.9%) when testing was undertaken in
community pharmacies, which was similar to that reported from gen-
eral practices (Adams et al., 2004), but lower than that reported for
internet-based testing (Gaydos et al., 2011).
The second review, undertaken by Gudka et al. (2013), included ten
relevant studies from the USA, UK, Australia and the Netherlands, and
compared two different community pharmacy approaches to chlamydia
testing: (i) population-based; and (ii), opportunistic chlamydia testing.
The review showed that population-based screening had a higher rate
of return (38–63%), compared to opportunistic testing (12–28%).
3.2.3. Differential effects by demographic or socioeconomic factors
Out of the 15 included systematic reviews, seven reviews included
studies that reported the effects of community pharmacy interventions
by demographic or socioeconomic factors (Brown et al., 2016; Burson
et al., 2016; Elias et al., 2011; Gudka et al., 2013; Kapadia, 2013;
Lindsey et al., 2015; Nacopoulos et al., 2010).
Kapadia (2013) examined the profile of patients undertaking chla-
mydia screening and concluded the service was targeted mainly at
young people < 24 years of age, women receiving emergency contra-
ception or gay men. One of the included primary studies showed that
women who were older than 24 years, had received Year 12 or
equivalent education, were working full-time and were from a less
deprived area were more likely to accept the offer of a testing kit. This
review also highlighted that there were mixed results in terms of uptake
of the test according to ethnic group. In terms of differences in the
uptake of SEPs, review-level evidence by Nacopoulos et al. (2010) de-
monstrated that ethnic minority men represented the largest portion of
participants using such a service, while women were less likely to use
the service. The review on cancer screening by Lindsey et al. (2015)
identified one primary study that examined breast and cervical cancer
screening uptake among low and moderate income women, and con-
cluded community pharmacies could be used to identify ‘at risk’ pa-
tients. A targeted approach to osteoporosis screening was reported in
the review by Elias et al. (2011), whereby people living in suburban and
rural communities were the main focus of the intervention. Burson et al.
(2016), who reviewed pharmacy-based immunisation services, showed
the impact of vaccination uptake on social and geographical inequal-
ities was mixed: some studies showed that community pharmacies lo-
cated in poor and/or ethnically diverse areas were less likely to offer
inoculation services; these pharmacies also had lower vaccination rates,
compared to pharmacies located in more affluent areas. However, the
review also showed there was a broad uptake of vaccination services
delivered through community pharmacies across a variety of ethnic
groups. Finally, the review by Brown et al. (2016) was unique in
comparison to the other included reviews in that it set to explicitly
explore how the interventions affected inequalities in health: while
none of the included studies reported subgroup analysis of treatment
effect by socioeconomic status, three primary studies adopted a tar-
geted approach to address inequality and specifically recruited parti-
cipants from deprived areas.
4. Discussion
This review presents the best available evidence on the effectiveness
of community pharmacy delivered public health interventions. Fifteen
systematic reviews were included in this review of reviews, comprising
157 unique primary studies. There were a number of community
pharmacy initiatives with clear positive intervention effects on primary
disease prevention: those focusing on smoking cessation, weight man-
agement, SEPs, and inoculation services. The intervention effects of
services focusing on secondary prevention (e.g. screening interventions)
were less clear, given many studies did not report how such interven-
tions supported the early diagnosis of disease. There was limited re-
view-level evidence examining the effects of the interventions on health
inequalities, as few studies reported sub-group analyses based on the
PROGRESS-Plus framework. While this may be the result of the sys-
tematic reviews failing to report all relevant published subgroup out-
comes, it is more likely to reflect that the primary study evidence base
has not considered outcomes according to PROGRESS-Plus. The ma-
jority of the studies reporting health inequalities described in this re-
view evaluated targeted interventions (i.e. interventions targeted to-
wards people of low SES). Other types of interventions used to target
health inequalities include interventions focused upon narrowing the
gap between the least and most disadvantaged (the gap approach),
while others can focus on reducing the social gradient in health (the
gradient approach), although our review did not find any examples of
these in the literature. Our review has also highlighted limited evidence
that suggests some interventions have potential to increase health in-
equalities – potentially leading to so-called ‘intervention generated in-
equalities’ (Lorenc et al., 2013). One such example was chlamydia
testing, whereby older, more educated women, from less deprived areas
were more likely to access the service.
This review has many strengths: our search strategy was broad and
wide-ranging, which included an inclusive database and grey literature
search. In addition, no language or date restrictions were applied to our
search strategy. We also did independent study selection and applied a
well-validated quality appraisal tool. Consequently, the reviews pre-
sented here, and the list of primary studies for which they report, detail
the health effects for the majority of the relevant studies available at the
time of our search.
A limitation of the final included reviews was their study designs, as
several did not assess the quality of the included primary studies.
Furthermore, the differential effects of the interventions by demo-
graphic or socioeconomic factors were limited, in part due to the re-
porting practices by both the primary study and systematic review
authors. Therefore, like all review of reviews, we have only synthesised
the results of existing systematic reviews and the relevant primary
studies included within them (Thomson et al., 2018). It is likely that in
a number of intervention areas, additional primary evaluations have
been conducted either after the systematic reviews have been com-
pleted, or perhaps they did not fit the inclusion criteria for the sys-
tematic reviews. Furthermore, it is possible that there is publication
bias (that negative results are less likely to be published) with regards
to the primary studies. Positive intervention effects in primary studies
are compounded in systematic reviews (and thus review of reviews) as
the primary study evidence base may be distorted. This review of re-
views is, therefore, a synthesis of the findings from published sys-
tematic reviews, not a synthesis of all primary studies of such inter-
ventions. Finally, the included systematic reviews in this review of
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reviews were focused almost exclusively on high-income countries,
despite an inclusive PICOS, which sought to include studies from any
country. Only four primary studies were from low or middle income
countries (Thailand and South Africa) representing 2.5% of the unique
primary studies identified here. In view of this, the findings from this
review of reviews are not necessarily transferable to community phar-
macies located in low or middle income countries and further primary
studies and subsequent reviews should seek to address this important
gap.
This review supports the policy shift of community pharmacies
delivering public health programmes to improve health, and prevent
disease – particularly those aimed at primary prevention. It is clear that
any future initiatives regarding community pharmacy and public health
should be underpinned by the best available evidence; for example,
previous community pharmacy campaigns have employed interven-
tions focused on reducing alcohol misuse when the literature suggests
such interventions have no impact on health or health behaviour.
This work also highlighted some important gaps in the literature
regarding community pharmacy and public health services. The ma-
jority of the included systematic reviews included interventions di-
rected towards physical health; there were no systematic reviews that
exclusively focused on public mental health interventions. We note that
a number of primary studies have been undertaken exploring the role of
the community pharmacist in screening for depression (see, for ex-
ample, (Kondova et al., 2018; Wilson and Twigg, 2018)), with others
focusing on interventions preventing the development of depression
(ISRCTN registry, 2017), but as yet, no systematic reviews have ex-
plored the effect of community pharmacy-based services on public
mental health. Given the association between mental and physical
health, and that mental health conditions are a significant cause of
overall disease burden worldwide, it would be sensible for future sys-
tematic reviews to explore this.
5. Conclusions
This review supports the development of some community phar-
macy public health services – particularly those focused on the primary
disease prevention. At present, little is known how community phar-
macy-delivered public health interventions impact on health inequal-
ities. It would be prudent for future studies to address this by explicitly
reporting outcomes according to the PROGRESS-Plus framework.
Abbreviations
AMSTAR 2 Assessment of Multiple Systematic Reviews
DARE Database of Abstracts of Reviews of Effects
PICOS criteria for inclusion and exclusion of studies
PROGRESS-Plus acronym to identify population and individual char-
acteristics across which health inequities may exist
PROSPERO international prospective register of systematic reviews
RCT randomized controlled trial
SEPs syringe/needle exchange programmes
Competing interests
The authors declare they have no competing interests.
Authors' contribution
AT designed and oversaw the study with KT and FHB. KT, FHB and
NW conducted the searches, reviewed articles for inclusion, extracted
data and conducted quality appraisal. KT, FHB and NW independently
reviewed the extracted data. KT and AT drafted the manuscript with
input from CB, FHB, NW and MB. All authors read and approved the
final manuscript.
Acknowledgements
This article is part of the HiNEWS project – Health Inequalities in
European Welfare States funded by the NORFACE (New Opportunities
for Research Funding Agency Cooperation in Europe) Welfare State
Futures programme (grant reference: 462-14-110). For more details on
NORFACE see www.norface.net/11. We thank Heather Robb (Durham
University) for her advice in developing the search strategy.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ypmed.2019.04.003.
References
Adams, E.J., Charlett, A., Edmunds, W.J., Hughes, G., 2004. Chlamydia trachomatis in the
United Kingdom: a systematic review and analysis of prevalence studies. Sex. Transm.
Infect. 80, 354–362.
Anderson, S., 2007. Community pharmacy and public health in Great Britain, 1936 to
2006: how a phoenix rose from the ashes. J. Epidemiol. Community Health 61, 844.
Ayorinde, A.A., Porteous, T., Sharma, P., 2013. Screening for major diseases in commu-
nity pharmacies: a systematic review. Int. J. Pharm. Pract. 21, 349–361.
Bambra, C., Gibson, M., Sowden, A., Wright, K., Whitehead, M., Petticrew, M., 2010.
Tackling the wider social determinants of health and health inequalities: evidence
from systematic reviews. J. Epidemiol. Community Health 64, 284–291.
Becker, L., Oxman, A., 2008. Overviews of reviews. In: Higgins, J.P.T., Green, S. (Eds.),
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, (updated
March 2011).
Blenkinsopp, A., Anderson, C., Armstrong, M., 2003. Systematic review of the effective-
ness of community pharmacy-based interventions to reduce risk behaviours and risk
factors for coronary heart disease. J. Public Health Med. 25, 144–153.
Brown, T.J., Todd, A., O'Malley, C., Moore, H.J., Husband, A.K., Bambra, C., Kasim, A.,
Sniehotta, F.F., Steed, L., et al., 2016. Community pharmacy-delivered interventions
for public health priorities: a systematic review of interventions for alcohol reduction,
smoking cessation and weight management, including meta-analysis for smoking
cessation. BMJ Open 6:e009828.
Burson, R.C., Buttenheim, A.M., Armstrong, A., Feemster, K.A., 2016. Community phar-
macies as sites of adult vaccination: a systematic review. Hum. Vaccin. Immunother.
12, 3146–3159.
Cairns, J., Warren, J., Garthwaite, K., Greig, G., Bambra, C., 2015. Go slow: an umbrella
review of the effects of 20mph zones and limits on health and health inequalities. J.
Public Health 37, 515–520.
Elias, M.N., Burden, A.M., Cadarette, S.M., 2011. The impact of pharmacist interventions
on osteoporosis management: a systematic review. Osteoporos. Int. 22, 2587–2596.
Gaydos, C.A., Barnes, M., Aumakhan, B., Quinn, N., Wright, C., Agreda, P., Whittle, P.,
Hogan, T., 2011. Chlamydia trachomatis age-specific prevalence in women who used
an internet-based self-screening program compared to women who were screened in
family planning clinics. Sex. Transm. Dis. 38, 74–78.
Gordon, J., Watson, M., Avenell, A., 2011. Lightening the load? A systematic review of
community pharmacy-based weight management interventions. Obes. Rev. 12,
897–911.
Gudka, S., Afuwape, F.E., Wong, B., Yow, X.L., Anderson, C., Clifford, R.M., 2013.
Chlamydia screening interventions from community pharmacies: a systematic re-
view. Sex. Health 10, 229–239.
Higgins, J., Deeks, J.J., 2011. Chapter 7: selecting studies and collecting data, in: Higgins,
J.P.T., Green, S. (Eds.), Cochrane Handbook for Systematic Reviews of Interventions
Version 5.1.0 [updated March 2011], The Cochrane Collaboration.
Higgins, J.P.T., Green, S., 2011. Cochrane Handbook for Systematic Reviews of
Interventions, 5.1.0 ed. John Wiley & Sons Ltd, Chichester.
Hill, S., Amos, A., Clifford, D., Platt, S., 2014. Impact of tobacco control interventions on
socioeconomic inequalities in smoking: review of the evidence. Tob. Control. 23, e89.
Hillier-Brown, F., Bambra, C., Thomson, K., Balaj, M., Walton, N., Todd, A., 2017. The
effects of community pharmacy public health interventions on population health and
health inequalities: a systematic review of reviews protocol. Syst. Rev. 6, 176.
ISRCTN registry, 2017. Community Pharmacies Mood Intervention Study (CHEMIST).
BMC, London.
Kapadia, M.Z., 2013. Chlamydia screening in community pharmacies: a systematic lit-
erature review of the characteristics of service users and a meta-analysis of chlamydia
prevalence. Sex. Health 10, 1–8.
Kavanagh, J., Oliver, S., Lorenc, T., 2008. Reflections on developing and using
PROGRESS-Plus. Equity Updat. 2, 1–3.
Kondova, A., Todorova, A., Tsvetkova, A., Arnaoudova, M., Andreevska, K., Grekova, D.,
2018. Screening and risk assessment for depression in community pharmacy - pilot
study. J. IMAB 24, 1928–1931.
Lindsey, L., Husband, A., Nazar, H., Todd, A., 2015. Promoting the early detection of
cancer: a systematic review of community pharmacy-based education and screening
interventions. Cancer Epidemiol. 39, 673–681.
Lorenc, T., Petticrew, M., Welch, V., Tugwell, P., 2013. What types of interventions
generate inequalities? Evidence from systematic reviews. J. Epidemiol. Community
Health 67, 190.
K. Thomson, et al. Preventive Medicine 124 (2019) 98–109
108
Main, C., Thomas, S., Ogilvie, D., Stirk, L., Petticrew, M., Whitehead, M., Sowden, A.,
2008. Population tobacco control interventions and their effects on social inequalities
in smoking: placing an equity lens on existing systematic reviews. BMC Public Health
8, 6.
Nacopoulos, A.G., Lewtas, A.J., Ousterhout, M.M., 2010. Syringe exchange programs:
impact on injection drug users and the role of the pharmacist from a US perspective.
J. Am. Pharm. Assoc. 50, 148–157.
Nguyen, V.H., 2017. Community osteoporosis screening services for the prevention of
osteoporotic fractures in population health: a literature review. Int. J. Evid. Based
Healthc. 15, 43–52.
NICE, 2018. Community pharmacy: promoting health and wellbeing. In:
Recommendations for Research in Detail NICE Guideline NG102. NICE, London.
Saba, M., Diep, J., Saini, B., Dhippayom, T., 2014. Meta-analysis of the effectiveness of
smoking cessation interventions in community pharmacy. J. Clin. Pharm. Ther. 39
(3), 240–247.
Sawangjit, R., Khan, T.M., Chaiyakunapruk, N., 2016. Effectiveness of pharmacy-based
needle/syringe exchange programme for people who inject drugs: a systematic re-
view and meta-analysis. Addiction 112, 236–247.
Shea, B.J., Reeves, B.C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell,
P., Welch, V., et al., 2017. AMSTAR 2: a critical appraisal tool for systematic reviews
that include randomised or non-randomised studies of healthcare interventions, or
both. BMJ 358:j4008.
Sinclair, H.K., Bond, C.M., Stead, L.F., 2004. Community pharmacy personnel interven-
tions for smoking cessation. Cochrane Database Syst. Rev. (Issue 1):CD003698.
Thomson, K., Hillier-Brown, F., Todd, A., McNamara, C., Huijts, T., Bambra, C., 2018. The
effects of public health policies on health inequalities in high-income countries: an
umbrella review. BMC Public Health 18, 869.
Todd, A., Copeland, A., Husband, A., Kasim, A., Bambra, C., 2014. The positive pharmacy
care law: an area-level analysis of the relationship between community pharmacy
distribution, urbanity and social deprivation in England. BMJ Open 4, e005764.
Watson, M.C., Blenkinsopp, A., 2009. The feasibility of providing community pharmacy-
based services for alcohol misuse: a literature review. Int. J. Pharm. Pract. 17,
199–205.
Wilson, C., Twigg, G., 2018. Pharmacist-led depression screening and intervention in an
underserved, rural, and multi-ethnic diabetic population. J. Am. Pharm. Assoc. 58,
205–209.
K. Thomson, et al. Preventive Medicine 124 (2019) 98–109
109
